Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIR ZOSTER
NCT06262776Recruiting
- Sponsor
- Central Adelaide Local Health Network
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by Central Adelaide Local Health Network. Primary endpoint: Functional T cell memory. Started Mar 2024; status: recruiting.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06262776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06262776.